Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | APOB | P04114 | 1/20 | 0.44 |
| ▸ | MTTP | P55157 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785708 | 0.92 | HDAC1 (0.60) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3342665 | 0.92 | SLC2A1 (0.50) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3339697 | 0.88 | SLC2A1 (0.50) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3345474 | 0.87 | SLC2A1 (0.46) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3339975 | 0.86 | OPRM1 (0.52) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3340208 | 0.86 | HDAC1 (0.53) | SLC2A1HDAC1HTR5ADPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3340366 | 0.86 | HDAC1 (0.53) | SLC2A1HDAC1HTR5ADPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3339839 | 0.86 | OPRM1 (0.56) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3345140 | 0.86 | OPRM1 (0.53) | SLC2A1HDAC1OPRM1OPRD1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3339102 | 0.85 | HDAC1 (0.52) | SLC2A1HDAC1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | SLC2A1 4173/4885HDAC1 2440/4885OPRM1 2/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | SLC2A1 2287/4885HDAC1 1478/4885OPRM1 4/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SLC2A1 4173/4885HDAC1 2440/4885OPRM1 2/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SLC2A1 4173/4885HDAC1 2440/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.